Pfizer (PFE) Stock Forecast & Price Target

$29.02

+0.12 (+0.42%)

(As of 08/21/2024 ET)

Pfizer - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Based on 15 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 8 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for PFE.

Consensus Price Target

$34.54
19.04% Upside

High Forecast	$45.00
Average Forecast	$34.54
Low Forecast	$29.00

According to the 15 analysts' twelve-month price targets for Pfizer, the average price target is $34.54. The highest price target for PFE is $45.00, while the lowest price target for PFE is $29.00. The average price target represents a forecasted upside of 19.04% from the current price of $29.02.

Type	Current Forecast 8/23/23 to 8/22/24	1 Month Ago 7/24/23 to 7/23/24	3 Months Ago 5/25/23 to 5/24/24	1 Year Ago 8/23/22 to 8/23/23
Consensus Rating	Moderate Buy	Hold	Hold	Hold
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)	11 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$34.54	$34.50	$35.86	$46.35
Forecasted Upside	19.04% Upside	17.14% Upside	18.97% Upside	17.51% Upside

Get Pfizer Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.75	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	19.04% Upside	5,591.76% Upside	8.74% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/19/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$45.00 ➝ $45.00	+56.47%
8/7/2024	Daiwa America 0 of 5 stars	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
8/7/2024	Daiwa Capital Markets 1 of 5 stars		Upgrade	Neutral ➝ Outperform	$28.00 ➝ $34.00	+14.21%
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	+4.51%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $30.00	-3.23%
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$30.00 ➝ $31.00	+0.23%
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
5/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $29.00	+4.28%
5/2/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $36.00	+30.62%
3/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/23/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$36.00	+30.67%
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$32.00	+7.67%
12/14/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$42.00 ➝ $36.00	+37.35%
10/16/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$42.00 ➝ $35.00	+3.80%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $34.00	+0.71%
10/16/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$38.00 ➝ $39.00	+21.46%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+38.66%
6/29/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$47.00 ➝ $40.00	+10.22%
4/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $45.00	+12.92%
2/7/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$40.00	-8.24%
2/1/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$49.00 ➝ $48.00	+8.70%
2/1/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $46.00	+4.17%
12/13/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$47.00 ➝ $60.00	+15.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:34 AM ET.

PFE Forecast - Frequently Asked Questions

What is Pfizer's forecast for 2024?: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $34.54, with a high forecast of $45.00 and a low forecast of $29.00.
Should I buy or sell Pfizer stock right now?: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 8 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PFE shares.
Does Pfizer's stock price have much upside?: According to analysts, Pfizer's stock has a predicted upside of 15.27% based on their 12-month stock forecasts.
Has Pfizer been upgraded by Wall Street analysts recently?: Over the previous 90 days, Pfizer's stock had 2 upgrades by analysts.
What analysts cover Pfizer?: Pfizer has been rated by research analysts at Barclays, Cantor Fitzgerald, Daiwa America, Daiwa Capital Markets, UBS Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Pfizer more than its competitors?: Analysts like Pfizer less than other "medical" companies. The consensus rating score for Pfizer is 2.53 while the average consensus rating score for "medical" companies is 2.75. Learn more on how PFE compares to other companies.